Patient(Pt)-reported toxicities during breast cancer (BC) chemotherapy (CRx): Associations with pre-treatment (Tx) measures of quality of life (QOL) and Tx discontinuation.

546Background: CRx completion is essential to Tx effectiveness and may depend on pt-reported toxicities rated “moderate, severe or very severe” (MSVS) that mirror physician-assessed CTCAE grades 2-4. Methods: We prospectively collected pt-reported MSVS in pts with stage I-III BC at each cycle of conventional (neo)adjuvant CRx. Pts also completed a pre-Tx measure of QOL (Functional Assessment of Cancer Therapy-General). Results: 158 pts were mean age 54, 28% non-white, 37% ≤high school (HS), 56% married. 44% received anthracycline-based CRx. Pt-rated maximum toxicity level was 12% mild, 37% moderate, 33% severe, and 18% very severe. Mean number of toxicities rated MSVS was 4.5 (range 0-12), with 51% rating ≥4 toxicities as MSVS. In multivariable analysis (R2= 45%), un-married (p = .04), ≤HS (p = .03), lower pre-Tx QOL (p < .0001), and anthracycline-based CRx (p = .001) were associated with increased number of MSVS toxicities. 28 pts (18%) discontinued CRx. Mean number of MSVS toxicities was 5.5 (range 1-7)...